Wednesday, 1 October 2014

Screening is the cornerstone of early detection of breast cancer


Breast cancer is a leading health concern all over the world, and has emerged to be a leading cause of morbidity and mortality among women. In India, breast cancer accounts for 20% cases of cancer in women and is second only to cervix cancer. Trends indicate towards increased incidences of breast cancer to the tune of 50 to 100% in last 20-30 years. Breast cancer is most commonly reported in women but less than 1% cases occur in males also.


Breast cancer occurs at a site which can be easily noticed and thus ought to be detected and treated early. Studies revealed poor outcome and high fatality rate from breast cancer because of diagnosis of cancer in advanced stages. Although easily detectable by simple breast self examination, maximum (>90%) cases are still diagnosed in stage II, III and stage IV. The first sign of the lump or tumor is generally detected during breast self examination. Early detection of breast cancer can increase the chances of successful treatment and cure of the disease and also minimize the associated morbidity and mortality.

 Early manifestation


Usually, no symptoms can be detected in the early stages of breast cancer. But with the growth of the tumour, some or all of the following changes can be detected.

  1. A lump or thickening in or near the breast or underarm area
  2. Change in shape and size of the breast
  3. Dimpling or puckering in the skin of the breast
  4. Invagination of the nipple
  5. Unusual discharge from the nipple, especially if its bloody
  6. Scaly, red or swollen skin of breast, nipple or areola, or the skin may have ridges or pitting


Detection and diagnosis


Breast self examination (BSE), clinical breast examination (CBE) and mammography are the recommended screening test for early detection of breast cancer. If any of the screening test comes positive, then some more tests may be required to confirm the type, exact location and stage of breast cancer.

 Breast self examination (BSE)

BSE familiarize women with the normal appearance of their breast and aids in early detection of any abnormality including tumor. It encourages preventive health behavior and healthcare seeking behavior in woman. Finding a change in breast must be reported to a health professional as soon as it is found, though it doesn’t mean there is a cancer.

Clinical breast examination (CBE)

CBE is a physical examination of breast done by a health professional such as doctor or nurse. It should be a part of regular health checkup of a woman. CBE is done to find a lump or change in the breast which may indicate towards a serious problem, including breast cancer. It also helps in finding other problems such as mastitis or a fibroadenoma. Clinician examines each breast, underarm and collarbone area for changes in breast size, skin changes, or signs of injury or infection such as bruising or redness. Lumps are feeled through finger tips, lymph nodes near breast to see if they are enlarged. A hard, oddly shaped lump that do not moves is very likely to be cancer, but further tests are always needed for confirmatory diagnosis. A woman is always advised to have at least one CBE in a year which should be six monthly or quarterly after menopause.


Mammogram

A mammogram is an x-ray of the breast, used to look for breast disease in women who have symptoms of a breast problem viz. lump or a nipple discharge, or a patient referred by a clinician after CBE. Mammograms for diagnostic usually take 2 views, from different angles, of each breast. It includes more images of the area of concern. In some cases, special images known as cone or spot views with magnification are used to make a small area of abnormal breast tissue easier to evaluate.
A mammogram can help to decide that –
-          The abnormality is not worrisome, resulting in patient returning only for routine yearly mammogram
-          A lesion/abnormal area of tissue has a high likelihood of a benign tumour, patient needs to follow up in 4 to 6 months for another mammogram
-          The lesion is more suspicious and needs a biopsy to confirm if it’s a cancer

 Magnetic resonance imaging (MRI) and ultrasound

MRI and ultrasound is used along with mammogram to better examine and correct location of the suspicious area. MRI is used to determine actual size of the cancer and look for another cancer in the breast of previously diagnosed patients.
Ultrasound is less expensive and easy procedure compared with MRI. Ultrasound is also used to target a specific area of concern indicated by mammogram. It helps to distinguish between cysts and solid masses and also help in differentiating between benign and cancerous tuours.

Biopsy

Biopsy is done when mammograms and other imaging tests as well as physical exam indicates a breast change from normal, possibly cancer. A biopsy is the only way to tell if cancer is really present.
A tissue sample of the suspicious area is taken for cytological examination of the tissue taken. Several type of biopsies are used, such as fine needle aspiration (FNA) biopsy, core biopsy and surgical biopsy. FNA is done with a fine needle, if required with the help of ultrasound to guide the needle to desired tissue. FNA is generally most accurate and easy type of biopsy. Core needle biopsy is similar to FNA but it uses a larger needle. Surgical biopsy is rarely done for breast cancer diagnosis. It is done in surgical outpatient to take a large sample of the suspect mass of tissue.
Management after diagnosis
After confirmation through biopsy about the presence of cancerous cells in the breast, management of the tumour cells starts. It is a long and hard fought battle with comparatively good results in terms of survival (≈ 90% 5-year relative survival rate ) in cases which are diagnosed in early stages i.e. stage 1. Sometimes doctors may suggest additional lab tests to assist with prognosis. The two most common lab tests are A) Hormone receptor test and B) the HER2/neu test. These tests can provide an insight into the suitability of most effective treatment options. Treatment options depend on the stage of cancer, it may include chemotherapy, radiation therapy, hormonal therapy or surgery.

Reference:

1.      Peepliwal AK, Tandale P. Breast cancer in India: Etiology, diagnosis and therapy. Research and Reviews: Journal of Medical and Health Sciences. 2013; 2(2): 31-42.
2.      Shrivastava SRBL, Shrivastava PS, Ramasamy J. Self breast examination: A tool for early diagnosis of breast cancer. Am J Public Health. 2013; 1(6):135-139.
3.      American Cancer Society. Clinical Breast Exam. http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs-clinical-breast-exam Revised January 28, 2014; Accessed September 30, 2014.
4.      WebMD. Clinical breast examination. http://www.webmd.com/women/clinical-breast-examination  Accessed September 30, 2014.
5.      American Cancer Society. How breast cancer is diagnosed? http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-diagnosis Accessed September 30, 2014.






International Day of Older Persons, 1 October 2014: The New Power

"Ageing is a development issue. Healthy older persons are a resource for their families, their communities and the economy."

WHO Brasilia declaration on healthy ageing, 1996.
Improved healthcare and better quality of life worldwide is responsible a substantial percentage of the population to reaching >60 years of age. Currently the number in of elderly people worldwide is 600 million and is expected to double by 2025 and reach approximately to two billion by 2050. 

This special population who has lead our lives, supported us when we were children, gave wings to our dreams are still playing a crucial role in the society:
  • Through volunteer work
  • Transmitting experience and knowledge
  • Helping their families with caring responsibilities and
  • Increasing their participation in the paid labor force

Turacoz salutes the elderly population for their invaluable support and role in our existence and wishes that they enjoy adequate levels of health. Geriatric medicine plays a big role  in the health outcomes of this special population.
Read more at http://www.who.int/ageing/events/idop_rationale/en/

Tuesday, 30 September 2014

Turacoz's initiative: Spreading Awareness of Breast cancer

We decide the first day of our cancer diagnosis whether we are going to be victims or survivors. We decide to muster up all our strength to fight to win. We decide to stay positive and not let cancer define us. We decide how we are going to handle each day. Yes, there are good days and bad days, but our attitudes determine each day. Hold on to your hopes, dreams, faith and determination, and gather strength from your support systems, because in the fight against cancer, we cannot give up.

Breast Cancer Awareness Month (BCAM), also referred to as National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and to raise funds for research into its cause, prevention, diagnosis, treatment and cure. The campaign also offers information and support to those affected by breast cancer.
October is Breast Cancer Awareness Month, which is an annual campaign to increase awareness of the disease. While most people are aware of breast cancer, many forget to take the steps to have a plan to detect the disease in its early stages and encourage others to do the same. We have made a lot of progress but still have a long way to go.

Turacoz healthcare solutions  understands its social responsibility and is passionate about improving understanding of breast cancer in India and worldwide. Through this medium we intend to spread the word in these  31 days of October’s Breast Cancer Awareness Month (BCAM). This is a critical opportunity to promote breast cancer awareness, share information and provide women across the world with better access to breast cancer care, treatments and services. We will keep you updated with information about the screening, diagnosis, disease management and recent advances in the field of breast cancer. We will also be interacting with healthcare professionals dealing with breast cancer patients, to understand the unmet needs, gaps in medical education and their perspective about the disease.  Turacoz also plans to share some inspiring stories of breast cancer survivors.

On the eve of BCAM, let’s all take a pledge to increase the awareness of this treatable disease if detected early. Turacoz would like to know the steps taken up by you to spread awareness of this dreadful disease in your respective areas.

#FightBreastCancer; #BreastCancerAwarenessMonth

Monday, 29 September 2014

Cardiovascular diseases increasing in Teenagers: Wakeup call on World Heart Day, 29 Sep 2014

Just one day prior to the “World Heart Day”, a school survey conducted from 25 public and private schools in Delhi and NCR region including 3000 students has come out with alarming figures:
  • 10% of school children between 13-16 years of age are overweight.
  • 35% increased risk of cardiovascular diseases (CVD) in the obese children
  • Average age of patients with heart diseases is showing a decline from 50 years to 20 years
  • Higher risk of 38% Risk of CVD is highest (38%) in obese young adults with risk factors and lowest (8%) in those with normal weight and no risk factors.
Preventive steps to be taken by the parents and school are to help and motivate the child to adopt a healthy lifestyle:
  • Diet modifications: less of fast/packaged foods , less sugar and trans-fat and consuming nutritious healthy home cooked foods
  • Improving the physical activity by including a compulsory exercise or sports regimen
  • Educating parents, children and involving schools in this movement.
In a cross sectional study conducted on 854 high school children, 81% of children were found to have insufficient physical activity with daily consumption of soup, salad or vegetables, and fruit, respectively to be as, 37%, 39% and 21%.
The risk factors in this population were:
  • Overweight-16%
  • Smoking-13%
  • Hypertension-11%
  • Impaired glucose metabolism-9%
  • Hypertriglyceridemia - 9%
  • Hypercholesterolemia - 5%
Poor physical activity, hypertension and overweight were more prevalent in males (p<0.001) whereas females had higher levels of cholesterol (p<0.005) and triglycerides (p<0.001).
Epidemic of childhood obesity becoming prevalent now is an important contributing factor for CVD and mortality in adults now. Many epidemiologic studies have observed that obesity has an impact on the cardiac autonomic modulation which can cause sympathetic overflow and reduced parasympathetic modulation. There is enough evidence to state that life style modifications including diet and physical activity can improve the CAM in the obese and reduce the burden of CVD in the adults.
As parents and healthcare professionals, this should act as an eye opener and we should turn back to basics with healthy home cooked foods, playing physically and restriction of TV, computers and sedentary activities.
Sources:
  1. Press release: Overweight kids in Delhi-NCR are more prone to cardiovascular diseases: ASSOCHAM. Available at http://assocham.org/prels/shownews.php?id=4705
  2. Rocha T et al. Cardiovascular risk profile of high school students: A cross-sectional study.Rev Port Cardiol. 2014 Sep 12. pii: S0870-2551(14)00182-6.
  3. Liao D et al. Childhood obesity and autonomic dysfunction: risk for cardiac morbidity and mortality.Curr Treat Options Cardiovasc Med. 2014 Oct;16(10):342.

Sunday, 28 September 2014

Save Her Heart - World heart day 29th september

‘Women can’t get heart attacks’- it is a biggest myth. Since 1984, more women than men have died of heart disease each year and yet much of the medical community still largely considers it a “men’s disease.”

Do you know Heart disease kills ten times more women than breast cancer each year, more than all other cancers combined? You may be surprised to know that that 1 out of every 3 women will develop heart disease in their lifetime, and this number is getting closer to 1 in 2! 

"Cardiovascular disease kills 480,000 women a year, about one per minute".



On this #worldheartday, let’s all of us pledge to save a woman’s heart. Be it your mother, sister, daughter or yourself. The good news is there is a lot you can do to reduce your risk of developing heart disease. The earlier you start thinking about your heart, the better it is.

Know your symptoms

 ‘Women may have less extreme symptoms of heart disease than men, so they may be more likely to ignore warning. The most important thing is for women to listen to their guts, and to make sure their doctor takes their complaints serious. 
  • ·         Increased shortness of breath with customary activities
  • ·         Unusual extreme fatigue*
  • ·         Significant indigestion especially with exertion
  • ·         Feelings of nausea/vomiting
  • ·         Dizziness
  • ·         Pain or pressure in the back or high chest, between shoulder blades
  • ·         Pain or discomfort (pressure) in one or both arms, neck, jaw, back, shoulder or stomach
Attack the #heartattack

'Let’s accept, women worry - just not about themselves.'

Mothers, wives, daughters – they will care about their family but forget to care about themselves.As a woman, you are the heart of a family; just imagine their life without you. Don’t you think you need to protect your heart? Ladies, here are the best things you can do to prevent heart disease are:
  • Take responsibility for your health.
  • Chose a healthy lifestyle
  • Eat & Cook heart-healthy
  • Control your weight.
  • Get regular physical activity.
  • Don’t smoke.
  • Lower your LDL cholesterol (the "bad" type). 
  • Control your blood pressure.
  • Relax
Finally, saw this new Saffolalife advertisement yesterday. Watch it and pledge to protect her heart on this #worldheartday. #saveherheart #worldheartday #protect her heart




Tuesday, 23 September 2014

Europe approves Gilead's cancer drug Zydelig amid challenging pricing environment

Less than two months after the FDA approved Gilead Sciences' ($GILD) first cancer drug, 
Zydelig, the European Medicines Agency (EMA) has followed suit, green-lighting the drug for use in treating two blood cancers. The approval puts Gilead well on track to meet analyst expectations that Zydelig (idelalisib) will be hauling in $1.2 billion in annual sales by 2020, though there's little doubt Gilead will face pressure from European health agencies to keep a lid on the new drug's price.

Zydelig is among a new class of drugs known as PI3k inhibitors. It was approved in the U.S. to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma. The EMA approved the drug for use in CLL and FL. In CLL, the approval was supported by late-stage data showing that when added to Roche's ($RHHBYRituxan, Gilead's drug prevented the cancer for progressing for twice as long as Rituxan alone, according to the Gilead statement. The EMA approved the drug f"Although chemo-immunotherapy is initially used to treat both CLL and FL, relapse is common and many patients run out of treatment options to treat the disease as it progresses," said Peter Hillmen, a professor and hematologist at Britain's Leeds Teaching Hospitals NHS Trust, in a statement released by Gilead. "Thus, Zydelig is a welcomed treatment option that offers a new approach in the management of these cancers."
No word yet on how Gilead plans to price Zydelig in Europe, but the company will likely face questions, particularly from the National Institute for Health and Care Excellence (NICE), the U.K.'s drug-price watchdog, which decides what drugs will be covered by the government. NICE has said "no" to several pricey cancer drugs lately, including Roche's Kadcyla for breast cancer, and Johnson & Johnson's ($JNJ) prostate cancer treatment Zytiga.
In September, NICE threatened to bypass drugmakers altogether when assessing the value of new drugs and instead go to the EMA to obtain clinical trial data.
Gilead itself has gotten some pushback from NICE on its new hepatitis C treatment Sovaldi. The drug is priced at $57,000 a course in the U.K.--much lower than its $84,000 price in the U.S.--but NICE still went back to Gilead in June and asked for more evidence that Sovaldi is worth its price. NICE issued a provisional OK in August and is expected to release its final appraisal on Sovaldi later this year.
In the U.S., analysts are reporting that Gilead has priced Zydelig lower than its top competitor, Johnson & Johnson's Imbruvica (ibrutinib)--$7,200 per month vs. $8,200. When added to Rituxan or another cancer treatment, however, the cost of Gilead's therapy could rise to $12,000, they estimate.
Zydelig won't be competing for market share on price alone. Analysts warn that in the U.S., pickup could be slowed by a black-box warning on the product that highlights such side effects as colitis, lung inflammation and potential fatal liver problems. Imbruvica doesn't have a black box. And there's more competition to come: AbbVie's ($ABBV) Rituxan.

Read More About Gilead's statement.


P.S. : Contact Turacoz Healthcare Solutions for any requirement in medical communications. Turacoz team is comprised of qualified medical writers with an experience ranging from 3 years to 30 years. The team is well equipped to take on projects of regulatory writing, scientific publications and medico-marketing related documents






Wednesday, 17 September 2014

New Deal : Merck licenses experimental psoriasis drug to India's Sun Pharma

Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million. Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications. The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease. 




Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said. Merck's shares were down about 1 percent at $59.41 on the New York Stock Exchange on Wednesday. Sun Pharmaceutical's shares closed at 792.40 rupees on the National Stock Exchange of India.
P.S. : Contact Turacoz Healthcare Solutions for any requirement in medical communication for pharmaceutical and biotech companies. Turacoz team is comprised of qualified medical writers with an experience ranging from 3 years to 30 years. The team is well equipped to take on projects of regulatory writing, scientific publications and medico-marketing related documents. They have thorough knowledge and understanding of ICH guidelines in different geographical regions, medical writing guidelines by ICMJE (International Committee of Medical Journal Editors), and region wise/client specific assignments.